Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507416 · ClinicalTrials.gov registry record · Phase 3
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
NCT00507416 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 502 participants.
The verdict
NCT00507416, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
Study Summary
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Prednisone
- DRUG Bortezomib
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00507416
The ClinicalTrials.gov registry entry for NCT00507416 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00507416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00507416 about?
NCT00507416 is a clinical study titled "Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone". This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered can...
What is the current status of trial NCT00507416?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2007-06. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00507416?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Prednisone (DRUG), Bortezomib (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00507416?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.